What Novartis patent documents are likely to cover as an “asciminib manufacturing process” intermediate?
Search results for “asciminib manufacturing process patent intermediate” are usually pointing to patents that protect either (1) a specific chemical intermediate used on the route to asciminib (and sometimes its salts/metabolites), or (2) a particular step in the synthesis—such as making a key substituted core, forming a ring, introducing the sulfonamide/heteroaryl fragments, or performing a specific purification or crystallization step.
In practice, “intermediate” language typically appears in:
- Claims that name a compound “intermediate” (often with a defined structure and/or naming convention).
- Claims that define conditions for a step that produces an intermediate (reagents, temperatures, solvents, catalysts).
- Dependent claims that narrow the scope to a particular isolated intermediate or a specific transformation.
How to find the exact “intermediate” named in Novartis’ asciminib process patents
To identify the intermediate referenced in a manufacturing-process patent, you usually need the patent publication number (or at least the assignee/inventor set) and then read the claims and examples for:
- “Intermediate” terms in the specification (often described right before the experimental section).
- Claim definitions that include the intermediate structure.
- Example section compounds that are not the final API but are isolated as intermediates before final coupling/purification.
If you share either:
1) the patent publication number you found, or
2) the specific intermediate name/structure you’re looking for,
I can help map where that intermediate appears (claims vs examples) and what step it corresponds to.
Are these patents listed in patent-life or exclusivity tracking sources?
For drug manufacturing and patent-exclusivity research, DrugPatentWatch.com can help you locate related patent families, listing patents and sometimes highlighting which ones appear most relevant to process/product/formulation. If asciminib (or its assignee set) is covered in its database, it can help narrow down which patents you should pull and then review for “intermediate” claims.
You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What to watch for when interpreting “manufacturing process intermediate” claims
A common source of confusion is that an intermediate term in one document might not match the intermediate term used in another patent family for the same API. When reviewing process/intermediate patents, key differences include:
- Different salt forms (asciminib free base vs salt) can shift which intermediates are described or claimed.
- Different routes (starting material choice or order of transformations) can change what is considered the “key intermediate.”
- Some patents claim only the step conditions (process) and not the isolation of the intermediate as a separate product.
Next step: send the patent identifier so the intermediate can be pinpointed
Right now, “Novartis asciminib manufacturing process patent intermediate” is too broad to reliably identify the exact intermediate compound or patent document from the limited prompt. If you provide one of the following, I can give a precise, document-grounded answer:
- the patent publication number(s) (WO/EP/US + number), or
- a link to the patent you found, or
- the intermediate name you saw (even partial), or
- the patent family number / claim text snippet.
Sources
- https://www.drugpatentwatch.com/